TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 8730416

Group type: EXPERIMENTAL
Intervention: Calcium dialysate (CaD) of 1.75 mmol/l
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Calcium dialysate (CaD) of 1.25 mmol/l
Number of subjects: 18

Group type: COMPARATOR
Intervention: Standard calcium dialysate (SCaD)
Number of subjects: 18

Group type: COMPARATOR
Intervention: Low calcium dialysate (LCaD)
Number of subjects: 18
Study: 1407617

Group type: EXPERIMENTAL
Intervention: Antibiotic pretreatment of heart valve prostheses
Number of subjects: 1262

Group type: COMPARATOR
Intervention: Nontreated group
Number of subjects: 1262
Study: 3930246

Group type: EXPERIMENTAL
Intervention: Aspirin 0.45 mg kg‐1 day‐1
Number of subjects: 15

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 15
Study: 30543172

Group type: EXPERIMENTAL
Intervention: Perilla seed oil
Number of subjects: 182

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 182
Study: 29596213

Group type: EXPERIMENTAL
Intervention: Chewing gum
Number of subjects: 125

Group type: COMPARATOR
Intervention: Control
Number of subjects: 125
Study: 27388373

Group type: EXPERIMENTAL
Intervention: Preventive basic care management (PBCM)
Number of subjects: 99

Group type: COMPARATOR
Intervention: Care as usual (CAU)
Number of subjects: 99

Group type: EXPERIMENTAL
Intervention: PBCM
Number of subjects: 99
Study: 24612027

Group type: EXPERIMENTAL
Intervention: Superficial dermabrasion (16 weekly sessions)
Number of subjects: 32

Group type: COMPARATOR
Intervention: Topical tretinoin cream (0.05% daily)
Number of subjects: 32
Study: 22074015

Group type: EXPERIMENTAL
Intervention: HiRes 120
Number of subjects: 65

Group type: EXPERIMENTAL
Intervention: Harmony processor
Number of subjects: 65

Group type: COMPARATOR
Intervention: HiRes
Number of subjects: 65
Study: 19854610

Group type: EXPERIMENTAL
Intervention: Dabigatran etexilate (DAB) 110 mg
Number of subjects: 512

Group type: EXPERIMENTAL
Intervention: Dabigatran etexilate (DAB) 150 mg
Number of subjects: 512

Group type: EXPERIMENTAL
Intervention: Dabigatran etexilate (DAB) 220 mg
Number of subjects: 512

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 512
Study: 17913961

Group type: EXPERIMENTAL
Intervention: TNF-alpha -308 G/A allele frequencies in women with pregnancy complications (cases)
Number of subjects: 1652

Group type: COMPARATOR
Intervention: TNF-alpha -308 G/A allele frequencies in women without pregnancy complications (controls)
Number of subjects: 1652

Group type: EXPERIMENTAL
Intervention: TNF-alpha -308 G/A genotype distributions in women with pregnancy complications (cases)
Number of subjects: 1652

Group type: COMPARATOR
Intervention: TNF-alpha -308 G/A genotype distributions in women without pregnancy complications (controls)
Number of subjects: 1652

Group type: COMPARATOR
Intervention: Comparison of TNF-alpha -308 G/A genotype distributions between cases and controls
Number of subjects: 1652

Group type: COMPARATOR
Intervention: Comparison of TNF-alpha -308 G/A allele frequencies between cases and controls
Number of subjects: 1652
Study: 15911462

Group type: EXPERIMENTAL
Intervention: Zinc as an adjuvant to malaria therapy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 12126383

Group type: EXPERIMENTAL
Intervention: Carbon dioxide dry ice sticks (CO2)
Number of subjects: 15

Group type: COMPARATOR
Intervention: Refrigerant spray (RS)
Number of subjects: 15
Study: 10726107

Group type: EXPERIMENTAL
Intervention: Postprandial lipemia (200 ml of 30% cream) in IHD patients
Number of subjects: 30

Group type: COMPARATOR
Intervention: Postprandial lipemia (200 ml of 30% cream) in healthy controls
Number of subjects: 30
Study: 7862217

Group type: EXPERIMENTAL
Intervention: Standard procedure (SP) for determining hypertension as described by the DCGP
Number of subjects: 94

Group type: EXPERIMENTAL
Intervention: First blood pressure measurement high (diastolic pressure 105-115 mmHg)
Number of subjects: 94

Group type: EXPERIMENTAL
Intervention: First blood pressure measurement low (diastolic pressure 95-105 mmHg)
Number of subjects: 94

Group type: COMPARATOR
Intervention: Ambulatory blood pressure measurement (ABM)
Number of subjects: 94
Study: 1786763

Group type: EXPERIMENTAL
Intervention: Accelerated hyperfractionation with twice-a-day irradiation (Group B)
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Accelerated hyperfractionation with three-times-a-day irradiation (Group C)
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Routine fractionation (Group A)
Number of subjects: 80
Study: 7050702

Group type: EXPERIMENTAL
Intervention: Rimantadine
Number of subjects: 450

Group type: EXPERIMENTAL
Intervention: Amantadine
Number of subjects: 450

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 450
Study: 31581816

Group type: EXPERIMENTAL
Intervention: Web-based pre-screening
Number of subjects: 19022

Group type: EXPERIMENTAL
Intervention: Multi-step, semi-automated screening process
Number of subjects: 19022

Group type: EXPERIMENTAL
Intervention: Centralisation and automation of screening activities
Number of subjects: 19022
Study: 29713841

Group type: EXPERIMENTAL
Intervention: Glycolic acid peel 70%
Number of subjects: 20

Group type: COMPARATOR
Intervention: Fractional CO2 laser resurfacing
Number of subjects: 20
Study: 26725988

Group type: EXPERIMENTAL
Intervention: Face Mask Ventilation (FMV)
Number of subjects: 41

Group type: COMPARATOR
Intervention: Nasal Mask Ventilation (NMV)
Number of subjects: 41

Group type: EXPERIMENTAL
Intervention: Nasal Mask Ventilation (NMV) with MCM
Number of subjects: 41
Study: 25378507

Group type: EXPERIMENTAL
Intervention: Simulator-trained group
Number of subjects: 48

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 48
Study: 22488038

Group type: EXPERIMENTAL
Intervention: First-line chronomodulated delivery of 5-fluorouracil, leucovorin and oxaliplatin
Number of subjects: 77

Group type: COMPARATOR
Intervention: Conventional delivery of 5-fluorouracil, leucovorin and oxaliplatin
Number of subjects: 77
Study: 21416914

Group type: EXPERIMENTAL
Intervention: Brush-free surgical scrub procedure (group B)
Number of subjects: 400

Group type: COMPARATOR
Intervention: Traditional surgical scrub technique (group A)
Number of subjects: 400

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 400
Study: 17390930

Group type: EXPERIMENTAL
Intervention: Standardized nursing intervention
Number of subjects: 0

Group type: COMPARATOR
Intervention: Spouses
Number of subjects: 0

Group type: COMPARATOR
Intervention: Patients
Number of subjects: 0
Study: 15592062

Group type: EXPERIMENTAL
Intervention: 4 mg tamsulosin once daily every day
Number of subjects: 140

Group type: EXPERIMENTAL
Intervention: 0.4 mg tamsulosin once daily every other day
Number of subjects: 140

Group type: COMPARATOR
Intervention: discontinued tamsulosin
Number of subjects: 140
Study: 12095019

Group type: EXPERIMENTAL
Intervention: Propofol (2.5 mg kg(‐1) plus fentanyl 1 microg kg(‐1))
Number of subjects: 60

Group type: COMPARATOR
Intervention: Sevoflurane (8% plus fentanyl 1 microg kg(‐1))
Number of subjects: 60

Group type: COMPARATOR
Intervention: Sevoflurane
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Propofol
Number of subjects: 60
Study: 10203562

Group type: EXPERIMENTAL
Intervention: High selenium diet (226.5 microg/d)
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: Selenate
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: Broccoli
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: Selenite
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: High selenium diet
Number of subjects: 27
Study: 7600031

Group type: EXPERIMENTAL
Intervention: Etoposide (50 mg/m2/day) p.o. for 21 consecutive days and cisplatin (100 mg/m2) i.v. on day 1 every 28 days for up to six courses
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Etoposide and cisplatin combination therapy
Number of subjects: 60
Study: 2167360

Group type: EXPERIMENTAL
Intervention: Porous hydroxyapatite (PHA)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Decalcified freeze‐dried bone allograft (DFDB)
Number of subjects: 12
Study: 220889

Group type: EXPERIMENTAL
Intervention: 10 mg of naloxone
Number of subjects: 7

Group type: EXPERIMENTAL
Intervention: Endorphin injections
Number of subjects: 7

Group type: EXPERIMENTAL
Intervention: Exogenous beta-endorphin
Number of subjects: 7
Study: 31614373

Group type: EXPERIMENTAL
Intervention: Endocuff vision device (EVD)
Number of subjects: 250

Group type: COMPARATOR
Intervention: Standard colonoscopy without cap
Number of subjects: 250
Study: 30821652

Group type: EXPERIMENTAL
Intervention: Exposure to cold air at 0, -10, and -17°C during rest and moderate-intensity exercise
Number of subjects: 34
Study: 28435487

Group type: EXPERIMENTAL
Intervention: IV acetaminophen
Number of subjects: 90

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 90
Study: 25599230

Group type: EXPERIMENTAL
Intervention: Spinal cord stimulation (SCS) ON
Number of subjects: 18

Group type: COMPARATOR
Intervention: Spinal cord stimulation (SCS) OFF
Number of subjects: 18
Study: 24341049

Group type: EXPERIMENTAL
Intervention: GIK solution
Number of subjects: 100

Group type: COMPARATOR
Intervention: Control group (non GIK)
Number of subjects: 100
Study: 20495801

Group type: EXPERIMENTAL
Intervention: Image-free computer-navigation system (navigated group)
Number of subjects: 64

Group type: COMPARATOR
Intervention: Free-hand technique (freehand group)
Number of subjects: 64
Study: 19808716

Group type: EXPERIMENTAL
Intervention: Supervised exercise training
Number of subjects: 217

Group type: COMPARATOR
Intervention: Aortoiliac revascularization with stent
Number of subjects: 217

Group type: COMPARATOR
Intervention: Optimal medical care
Number of subjects: 217
Study: 16704584

Group type: EXPERIMENTAL
Intervention: Potassium permanganate 8 mg.l(‐1)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Saline (Control)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Control
Number of subjects: 50
Study: 15035935

Group type: EXPERIMENTAL
Intervention: Mandatory drug testing program (SATURN) for high school student athletes
Number of subjects: 0
Study: 11168516

Group type: EXPERIMENTAL
Intervention: Interferon alfa 2b (IFN) 5.0 MU, three times a week for 1 year
Number of subjects: 223

Group type: COMPARATOR
Intervention: Control group (no treatment)
Number of subjects: 223
Study: 9037645

Group type: EXPERIMENTAL
Intervention: Protocol group (oxygen delivery targeted towards 600 ml/min/m2)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Protocol group
Number of subjects: 0
Study: 8198908

Group type: EXPERIMENTAL
Intervention: Propofol infusion for induction and maintenance (target concentration 8 micrograms ml-1)
Number of subjects: 163

Group type: COMPARATOR
Intervention: Propofol bolus (2.5-3.5 mg kg-1)
Number of subjects: 163

Group type: COMPARATOR
Intervention: Thiopentone (4-5 mg kg-1)
Number of subjects: 163

Group type: COMPARATOR
Intervention: Halothane (2-3% for induction, 1-2% for maintenance)
Number of subjects: 163
Study: 3280746

Group type: EXPERIMENTAL
Intervention: Nimodipine treatment
Number of subjects: 154

Group type: COMPARATOR
Intervention: Placebo treatment
Number of subjects: 154
Study: 31301164

Group type: EXPERIMENTAL
Intervention: 10-min attachment-prime (to enhance attachment-security)
Number of subjects: 68

Group type: COMPARATOR
Intervention: Interpersonal skills module (control condition)
Number of subjects: 68
Study: 30488350

Group type: EXPERIMENTAL
Intervention: Gemcitabine (G) 800 mg/m2 bi-weekly and Temsirolimus (T) 10 mg weekly, escalated until dose-limiting toxicities (DLTs) were reached.
Number of subjects: 85

Group type: EXPERIMENTAL
Intervention: Gemcitabine (G) and Temsirolimus (T) combination treatment.
Number of subjects: 85
Study: 26104022

Group type: EXPERIMENTAL
Intervention: Tailored therapy
Number of subjects: 1050

Group type: COMPARATOR
Intervention: Triple plus bismuth therapy
Number of subjects: 1050

Group type: COMPARATOR
Intervention: Concomitant therapy
Number of subjects: 1050
Study: 26258451

Group type: EXPERIMENTAL
Intervention: Integrated Training Group (ITG) - received RMT using an incentive respiratory spirometer and ADIM using a Stabilizer for 15 minutes a day, five times a week for 6 weeks
Number of subjects: 37

Group type: EXPERIMENTAL
Intervention: Integrated Training Group (ITG)
Number of subjects: 37

Group type: COMPARATOR
Intervention: Respiratory Muscle Training Group (RMTG)
Number of subjects: 37

Group type: COMPARATOR
Intervention: Control Group (CG)
Number of subjects: 37
Study: 24124451

Group type: EXPERIMENTAL
Intervention: OPAL-HIV-Gag(c) 12 mg
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: OPAL-HIV-Gag(c) 24 mg
Number of subjects: 23

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: OPAL-HIV-Gag(c)
Number of subjects: 23
Study: 21918162

Group type: EXPERIMENTAL
Intervention: Nebulization of ropivacaine 1%, 3 mL before and after surgery
Number of subjects: 60

Group type: COMPARATOR
Intervention: Instillation of ropivacaine 0.5%, 20 mL after induction of the pneumoperitoneum
Number of subjects: 60
Study: 18184832

Group type: EXPERIMENTAL
Intervention: Hydrogel coils
Number of subjects: 499

Group type: COMPARATOR
Intervention: Control (bare platinum coils)
Number of subjects: 499
Study: 17996052

Group type: EXPERIMENTAL
Intervention: Locomotor Training Program (LTP)
Number of subjects: 400

Group type: COMPARATOR
Intervention: Home Exercise Program (HEP)
Number of subjects: 400

Group type: EXPERIMENTAL
Intervention: LTP-Early
Number of subjects: 400

Group type: EXPERIMENTAL
Intervention: LTP-Late
Number of subjects: 400
Study: 15269135

Group type: EXPERIMENTAL
Intervention: Aromasin (25 mg daily)
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Femara (2.5 mg daily)
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Aromasin or Femara
Number of subjects: 36
Study: 11359133

Group type: EXPERIMENTAL
Intervention: 1 mL fibrin glue with 4% lidocaine chloride (group C)
Number of subjects: 74

Group type: EXPERIMENTAL
Intervention: 1 mL fibrin glue using CaCl2 as solution to dissolve thrombin (group B)
Number of subjects: 74

Group type: COMPARATOR
Intervention: Control group (group A)
Number of subjects: 74
Study: 9149330

Group type: EXPERIMENTAL
Intervention: D-fenfluramine (30 mg)
Number of subjects: 7

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 7
Study: 8481358

Group type: EXPERIMENTAL
Intervention: Neoadjuvant treatment with medroxyprogesterone acetate (MPA) 100 mg t.i.d. p.o. from diagnosis for 90 days
Number of subjects: 218

Group type: COMPARATOR
Intervention: No adjuvant treatment (control group)
Number of subjects: 218
Study: 2906343

Group type: EXPERIMENTAL
Intervention: Triphasic oral contraceptive containing ethinyl estradiol and levonorgestrel (LNG)
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: Triphasic oral contraceptive containing ethinyl estradiol and gestodene (GTD)
Number of subjects: 44
Study: 30900508

Group type: EXPERIMENTAL
Intervention: Clinical shoulder tests with a brief practical session
Number of subjects: 113

Group type: COMPARATOR
Intervention: Clinical shoulder tests without a brief practical session
Number of subjects: 113
Study: 31743998

Group type: EXPERIMENTAL
Intervention: Tai Chi program (3 times a week for 10 months)
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Tai Chi program
Number of subjects: 80

Group type: COMPARATOR
Intervention: Control group (routine treatments)
Number of subjects: 80
Study: 30366588

Group type: EXPERIMENTAL
Intervention: Telehealth (TH)
Number of subjects: 229

Group type: COMPARATOR
Intervention: Routine Clinical Practice (RCP)
Number of subjects: 229
Study: 27121007

Group type: COMPARATOR
Intervention: Endometrial injury by endometrial pipelle biopsy (PIP-IVF)
Number of subjects: 1470

Group type: COMPARATOR
Intervention: Endometrial injury by endometrial pipelle biopsy (PIP-UE)
Number of subjects: 1470

Group type: COMPARATOR
Intervention: Endometrial injury by endometrial pipelle biopsy (PIP-PCOS)
Number of subjects: 1470

Group type: COMPARATOR
Intervention: No intervention (PIP-IVF)
Number of subjects: 1470

Group type: COMPARATOR
Intervention: Sham procedure (PIP-UE)
Number of subjects: 1470

Group type: COMPARATOR
Intervention: Sham procedure (PIP-PCOS)
Number of subjects: 1470
Study: 24736035

Group type: EXPERIMENTAL
Intervention: Modified London Stroke Carers Training Course (LSCTC)
Number of subjects: 38
Study: 22548372

Group type: EXPERIMENTAL
Intervention: VVI
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: DDDR
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: DDDR with SBR
Number of subjects: 21
Study: 20406217

Group type: EXPERIMENTAL
Intervention: Propranolol 80 mg
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Bisoprolol 20 mg
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study: 18925531

Group type: EXPERIMENTAL
Intervention: Urine NGAL and IL-18 concentrations measured 2 hours postoperation, corrected for urine creatinine
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: Urine NGAL and IL-18 concentrations measured 2-4 hours postoperation
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: Logistic regression analysis of urine NGAL corrected for urine creatinine and urine IL-18 at 2 hours postoperation
Number of subjects: 33
Study: 16238558

Group type: EXPERIMENTAL
Intervention: Ring Block (RB) with 1-1.5 ml
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Dorsal Penile Block with 1.5-4 ml
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Combined Ring and Dorsal Penile Block with 2.5-5 ml
Number of subjects: 100
Study: 11991432

Group type: EXPERIMENTAL
Intervention: Contraceptive steroid treatment followed by estrogen replacement therapy
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Estrogen replacement therapy
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Combination of estrogens and a progestin
Number of subjects: 0

Group type: COMPARATOR
Intervention: No estrogen replacement therapy
Number of subjects: 0
Study: 10207207

Group type: EXPERIMENTAL
Intervention: Carotid surgery
Number of subjects: 108
Study: 7596116

Group type: EXPERIMENTAL
Intervention: Losartan potassium (100 mg)
Number of subjects: 8

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Losartan potassium (100 mg) after salt depletion
Number of subjects: 8

Group type: COMPARATOR
Intervention: Placebo after salt depletion
Number of subjects: 8
Study: 2193713

Group type: EXPERIMENTAL
Intervention: 10 mg flunarizine
Number of subjects: 102

Group type: EXPERIMENTAL
Intervention: 20 mg flunarizine
Number of subjects: 102

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 102
Study: 30298964

Group type: EXPERIMENTAL
Intervention: CNL+STEA
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: CNL+TEA
Number of subjects: 15

Group type: COMPARATOR
Intervention: CNL
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: CNL+sham-TEA
Number of subjects: 15
Study: 28165180

Group type: EXPERIMENTAL
Intervention: Faster-acting insulin aspart (faster aspart)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Insulin aspart (IAsp)
Number of subjects: 40
Study: 25758258

Group type: EXPERIMENTAL
Intervention: Waxy maize heat modified starch (WMHMS)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Uncooked corn-starch (UCCS)
Number of subjects: 10
Study: 23140261

Group type: EXPERIMENTAL
Intervention: Metformin (500 mg single dose)
Number of subjects: 62

Group type: COMPARATOR
Intervention: Control group (no metformin)
Number of subjects: 62
Study: 21856480

Group type: EXPERIMENTAL
Intervention: Omecamtiv mecarbil (0.5 mg/kg per h)
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: Omecamtiv mecarbil (various doses from 0.005 to 1.0 mg/kg per h)
Number of subjects: 34

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 34
Study: 19247541

Group type: EXPERIMENTAL
Intervention: Mitt use during therapy
Number of subjects: 24

Group type: COMPARATOR
Intervention: No mitt use during therapy
Number of subjects: 24
Study: 17215743

Group type: EXPERIMENTAL
Intervention: HMB
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: HMB/ARG/GLN
Number of subjects: 100

Group type: COMPARATOR
Intervention: PLAC
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: HMB and HMB/ARG/GLN
Number of subjects: 100
Study: 15507694

Group type: EXPERIMENTAL
Intervention: External nasal dilator strip (ENDS)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30

Group type: COMPARATOR
Intervention: Control
Number of subjects: 30
Study: 11737954

Group type: EXPERIMENTAL
Intervention: Low-glycaemic index-low-fat-high-protein diet
Number of subjects: 12

Group type: COMPARATOR
Intervention: American Heart Association (AHA) phase I diet
Number of subjects: 12

Group type: COMPARATOR
Intervention: Pair-fed session (same macronutrient composition as AHA diet)
Number of subjects: 12
Study: 9498287

Group type: EXPERIMENTAL
Intervention: Smoking cessation
Number of subjects: 182

Group type: COMPARATOR
Intervention: Continued smoking
Number of subjects: 182

Group type: COMPARATOR
Intervention: Continued smoking vs Smoking cessation
Number of subjects: 182
Study: 8049638

Group type: EXPERIMENTAL
Intervention: beta-carotene, vitamin E, and selenium
Number of subjects: 29584

Group type: EXPERIMENTAL
Intervention: retinol and zinc
Number of subjects: 29584

Group type: COMPARATOR
Intervention: riboflavin and niacin
Number of subjects: 29584

Group type: COMPARATOR
Intervention: vitamin C and molybdenum
Number of subjects: 29584
Study: 3189478

Group type: EXPERIMENTAL
Intervention: Biconvex intraocular lens
Number of subjects: 178

Group type: COMPARATOR
Intervention: Meniscus intraocular lens
Number of subjects: 178
Study: 1096536

Group type: EXPERIMENTAL
Intervention: Flupenthixol decanoate
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Fluphenazine decanoate
Number of subjects: 40

Group type: COMPARATOR
Intervention: Both drugs
Number of subjects: 40
Study: 31888723

Group type: EXPERIMENTAL
Intervention: Metoprolol (95 mg daily for 6 months)
Number of subjects: 130

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 130

Group type: EXPERIMENTAL
Intervention: Both groups (Metoprolol and Placebo)
Number of subjects: 130
Study: 28390325

Group type: EXPERIMENTAL
Intervention: Umbilical cord clamped at <15 seconds
Number of subjects: 156

Group type: EXPERIMENTAL
Intervention: Umbilical cord clamped between 60 ‐ 75 seconds
Number of subjects: 156

Group type: EXPERIMENTAL
Intervention: Umbilical cord clamped between 120 ‐ 135 seconds
Number of subjects: 156

Group type: EXPERIMENTAL
Intervention: Delayed cord clamping (DCC)
Number of subjects: 156

Group type: COMPARATOR
Intervention: Early cord clamping
Number of subjects: 156
Study: 26378681

Group type: EXPERIMENTAL
Intervention: Salsalate (2500-4500 mg for 4 days)
Number of subjects: 31

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 31
Study: 23694720

Group type: EXPERIMENTAL
Intervention: LY2140023 (40 mg BID)
Number of subjects: 261

Group type: COMPARATOR
Intervention: Standard of Care (SOC: olanzapine, risperidone, or aripiprazole)
Number of subjects: 261